Aduro’s pancreatic cancer drug fails in mid-stage study

16 May, 2016 11:15 pm

NEW YORK – Aduro Biotech Inc said its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, in a mid-stage study.

In the study, patients were given either CRS-207 or chemotherapy or a combination of CRS-207 with Aduro’s GVAX Pancreas, the company said on Monday.

Aduro’s shares fell 33 percent to $7.14 in premarket trading. –Reuters

Must Watch